Results 41 to 50 of about 11,568,194 (143)

Imaging spectrum of amyloid-related imaging abnormalities associated with aducanumab immunotherapy

open access: yesFrontiers in Radiology
Alzheimer's Disease (AD) is a leading cause of morbidity. Management of AD has traditionally been aimed at symptom relief rather than disease modification.
Houman Sotoudeh   +7 more
doaj   +1 more source

Insular volume abnormalities associated with different transition probabilities to psychosis [PDF]

open access: yes, 2011
Background Although individuals vulnerable to psychosis show brain volumetric abnormalities, structural alterations underlying different probabilities for later transition are unknown.
McGuire, P.   +52 more
core   +2 more sources

Symptomatic amyloid-related imaging abnormalities after Lecanemab treatment in an APOE ε4 homozygous patient with mild cognitive impairment due to Alzheimer's disease: one case report

open access: yesChinese Journal of Contemporary Neurology and Neurosurgery
Objective To report a case of symptomatic amyloid-related imaging abnormalities (ARIA) following Lecanemab treatment in patient with mild cognitive impairment due to Alzheimer's disease (AD-MCI), so as to provide references for the clinical safe ...
CAO Wen-wei   +5 more
doaj   +1 more source

Resting State fMRI Reveals Diminished Functional Connectivity in a Mouse Model of Amyloidosis [PDF]

open access: yes, 2013
Introduction: Functional connectivity (FC) studies have gained immense popularity in the evaluation of several neurological disorders, such as Alzheimer’s disease (AD). AD is a complex disorder, characterised by several pathological features. The problem
Rafael Delgado Y Palacios   +36 more
core   +2 more sources

Parenchymal and vascular Aβ-deposition and its effects on the degeneration of neurons and cognition in Alzheimer's disease [PDF]

open access: yes, 2008
The deposition of the amyloid β-protein (Aβ) is one of the pathological hallmarks of Alzheimer's disease (AD). Aβ-deposits show the morphology of senile plaques and cerebral amyloid angiopathy (CAA). Senile plaques and vascular Aβ-deposits occur first in
Griffin, W. Sue T.   +3 more
core   +1 more source

Anti-Amyloid Therapy, AD, and ARIA: Untangling the Role of CAA

open access: yes, 2023
Anti-amyloid therapies (AATs), such as anti-amyloid monoclonal antibodies, are emerging treatments for people with early Alzheimer’s disease (AD). AATs target amyloid β plaques in the brain.
Nho, Kwangsik   +9 more
core   +1 more source

Imaging for anti‐amyloid therapy eligibility: Comparing GRE and SWI in detecting microhemorrhages and superficial siderosis

open access: yesAlzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring
INTRODUCTION Anti‐amyloid therapies such as lecanemab require magnetic resonance imaging (MRI) screening to exclude patients with > 4 gradient‐recalled echo (GRE)‐detected microhemorrhages or any superficial siderosis (SS).
Jeremy N. Ford   +15 more
doaj   +1 more source

A fluorescent amyloid sensor for quantitative super-resolution imaging of amyloid fibril assembly. [PDF]

open access: yes, 2021
Many soluble proteins can self-assemble into macromolecular structures called amyloids, a subset of which are implicated in a range of neurodegenerative disorders.
Liam D., Adair   +4 more
core   +2 more sources

β-microglobulin amyloid fibril-induced membrane disruption is enhanced by endosomal lipids and acidic pH [PDF]

open access: yes, 2014
Although the molecular mechanisms underlying the pathology of amyloidoses are not well understood, the interaction between amyloid proteins and cell membranes is thought to play a role in several amyloid diseases. Amyloid fibrils of β-microglobulin (βm),
Eric W. Hewitt   +49 more
core   +1 more source

Spontaneous ARIA (Amyloid-Related Imaging Abnormalities) and Cerebral Amyloid Angiopathy Related Inflammation in Presenilin 1-Associated Familial Alzheimer's Disease [PDF]

open access: yes, 2015
Amyloid-related imaging abnormalities (ARIA), thought to reflect immune responses to vascular amyloid, have been detected in several amyloid-modifying therapy trials for Alzheimer's disease (AD).
Revesz, T   +5 more
core  

Home - About - Disclaimer - Privacy